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The use of Hericium erinaceus and Trametes versicolor extracts 
in supportive treatment in oncology
Substances available in nature with potential therapeutic 
effects are the subject of research that raises tremendous 
hopes for new challenges in medicine. Fungi are the most 
common organisms in the ecosystem and the most interest-
ing in this respect. This review discusses two species of 
edible fungi, used for centuries in Eastern natural medi-
cine, with the best-documented effect – Hericium erinaceus 
(He) and Trametes versicolor (Tv). The results of in vivo and in 
vitro studies conducted on mice and human cell lines demon-
strate immunomodulatory, potentially, anticancer, anti-
inflammatory and neuroregenerative effects of substances 
isolated from these fungi. The substances contained in the 
extracts of He and Tv seem to have immunomodulatory 
 effects that may support chemotherapy. The use of these 
extracts is justified stronger than the other supportive 
treat ments based on supplements.
Keywords: Hericium erinaceus, Trametes versicolor, onco logy, 
fungi, immunomodulation
INTRODUCTION
The healing properties of substances available in nature have been known for centu-
ries. Medical practices using extracts and infusions from plants have been described in 
detail by various civilizations. Many of the medicines currently in use are of natural ori-
gin. These include acetylsalicylic acid, salicylate derivative obtained from willow bark 
(Salix, 1853), digoxin, an alkaloid of digitalis (Digitalis lanata, 1925), morphine, poppy alka-
loid (Papaver somniferum, 1803) or the first anti-malarial drug – cinchona alkaloid quinine 
(Cinchona, 1820) (1, 2). One of the best-known natural medicines is penicillin. It was discov-
ered by Ernest Duchesne, author of the work Contribution to the Study of the Vital Competition 
in Microorganisms: Antagonism Between Moulds and Microbes (1897), and then isolated from 
fungus mold Penicillium notatum in 1929 by the later Nobel laureate Alexander Fleming (1). 
We also remind on the discovery of other antibiotics, e.g. vancomycin (Amycolaptosis orien-
talis, 1955) and erythromycin (Saccharopolyspora erythraea, 1952) from fungi (1). The research 
on modern antibacterial drugs produced by fungi, including cetromycin, is being continued. 
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(topotecan and irinotecan) and amrubicin – generation 3 anthracycline derived from the 
Streptomyces peucetius are used (1, 3).
It is estimated that less than 10 % of the world’s biodiversity has been assessed for po-
tential biological activity so far. This means that many potentially useful natural medicines 
are still waiting to be discovered (4). At the same time, numerous dietary supplements based 
on natural products containing substances with unproven or unconfirmed biological proper-
ties are available on the market. Their use during anticancer treatment, without doctors’ 
knowledge, may cause drug interactions and life-threatening complications.
This review article discusses two species, among many edible fungi, with the most 
documented immunomodulatory effect – Hericium erinaceus (He) and Trametes versicolor (Tv).
HERICIUM ERINACEUS
Hericium erinaceus (He) of Herinaceae family is a widespread, edible fungus popular 
in Asian countries, such as China (houtou, monkey head mushroom), Korea or Japan (yama-
bushitake). It is traditionally used to treat peptic ulcers and acute gastritis. Its extracts are 
attributed to antineoplastic, neuroregenerative, cardio-, hepato- and nephroprotective 
 effects, as well as improvement in glycemic and lipid profile control (5, 6).
As in the case of some other species of fungi, He extract has an antibacterial effect. It 
was demonstrated in an in vitro study of human gastric cells and in vivo research in mice 
infected with Helicobacter pylori (7). As a result of using an alcohol extract (2 mg mL–1) in 
the in vitro study, a shortened Helicobacter pylori survival in phosphate-buffered saline 
(PBS), in the absence of effects on Escherichia coli, and a decreased bacterial ability to adhere 
to gastric cells was demonstrated. In addition, a reduction in the H. pylori bacterial count 
was observed in the mouse organisms in the in vivo study.
He extract (in mice) exerted a protective effect on the chemically damaged mucous 
membrane of the stomach and intestines. The study showed that it prevented further dam-
age to the mucosa and promoted its regeneration by regulating the activity of neutrophils 
and lymphocytes, inhibiting the production of inflammatory mediators, such as TNF 
 alpha, interleukin-1β (IL-1β ), interleukin-6 (IL-6) and releasing substances that reduce 
oxidative stress (NO, malondialdehyde, peroxide dismutase) (8, 9).
Several biologically active ingredients have been detected in the He extract, including 
hericerones (meroterpenoids) obtained from the fruiting body (hericerin, hericerin A, 
hericenone J, isohericenone J, isoericerine, N-De-phenylethyl-isohericerin and 4-(3’,7’-di-
methyl-2’,6’-octadienyl)-2-formyl-3-hydroxy-5-methyoxybenzylalcohol), erinacines (cya-
thane diterpenoids) from the mycelium (erinacin A to K and P to S), He polysaccharide 
(HEP) and lectins (10). Fig. 1a gives the chemical structures of the components.
The effect of hericerin and hericerin A was investigated on human blast cells of acute 
promyelocytic leukaemia (HL60). Both substances inhibited the proliferation of leukemic 
cells and induced their apoptosis (10). Similar results were obtained by the authors of the 
study comparing the effect of various solutions obtained from the powdered fruit body of 
He on human leukemic cells MOLT-4 and U-937. Hot water extract (HWE) and microwave-
assisted 50 % ethanol extract (MWE) from powdered He fruit body in concentrations of 
500 mg mL–1 suppressed the growth of leukemic cells by inducing the apoptosis without 
affecting the normal human fibroblasts (HGF-1). The cytotoxic activity of HWE and MWE 
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extract was compared with the effect of a solution containing RNAse and propidium 
 iodide (according to the performance-based standards, PBS) and it resulted in 47 and 44 % 
decrease, resp. (11). In the same study, the authors compared the effect of the He extracts 
on the decrease of the mitochondrial membrane potential of human leukemic U-937 cells 
associated with the cytochrome c release. As in the previous observations, HWE and MWE 
extracts showed higher efficiency in decreasing the mitochondrial membrane potential in 
U-937 cells of 62.3 and 59.8 %, resp., as compared to the effect of etoposide used as a control.
The purified polysaccharide, named EP-1, extracted from He showed a selective pro-
apoptotic effect on human stomach pre-cancerous cells (MC), without damaging healthy 
cells (GES-1) (12). A more accurate study using HEG-5 polysaccharide performed on  human 
stomach cancer cells (SGC-7901) proved the dose-dependent inhibitory effect of this substance 
on the cancer cell proliferation, which reached 93.4 % at a concentration of 200 μg mL–1 
after 48 hours of incubation (13).
The results of the studies on the effect of He agglutinin (HEA) presented by Li et al. 
(14) show its inhibitory effect not only on human hepatocellular carcinoma and breast 
cancer cells but also on HIV-1 reverse transcriptase.
The apoptosis of tumour cells is dependent on the induction of nitric oxide (NO) pro-
duction in macrophages and the activation of mitochondrial caspases (caspase 9 and cas-
pase 3) (11). Additionally, the extracts from He increased the concentrations of pro-apop-
totic proteins (p53, Bax, Bad, Bid) and at the same time reduced the concentrations of 
anti-apoptotic proteins (Bcl-2, PI3K, CDK4, Akt).
A summary of the results on cell lines studies is presented in Table I.
Anticancer effects of M8 extract from 8 species of fungi including He, were tested in 
mice with intravenously administered adenocarcinoma cells colon 26-L5, showing a signi-
ficant dose-dependent (50–200 mg kg–1 daily) inhibition of the tumour cell dissemination 
to the lungs (15). Cytometric analysis of the blood of the tested mice showed a dose-depen-
dent increase of CD3, CD19, CD4 and CD8 cells, without affecting NK1.1 and Mac-1 cell 
numbers. Increased production of IFN-γ and IL-4 by splenocytes was also found in the 
treated mice compared to the control group.
It is suggested that the immune effect of the He polysaccharide (HEP) is associated 
with the activation of mitogen-activated protein kinases (MAPK) – ERK, JNK, p38, AKT 
(16). As a result, it strengthens the innate and acquired immune response by increasing the 
activity of NK cells and macrophages and increasing the production of lymphocytes in the 
spleen. In addition, the mice receiving HEP also had increased levels of intestinal IgA.
Apart from the potential anticancer properties, the most widely commented effect of 
the He extracts is the effect on the nervous system. There are reports of neuroprotective 
and neuroregenerative effects of erinacins contained in the He. Erianacin A administered 
to mice at a dose of 19 mg g–1 resulted in an increased proliferation of neural progenitor 
cells and the number of new neurons around the dentate gyrus and stimulation of nerve 
growth factor (NGF), blocking the kappa opioid receptor, reducing β-amyloid deposition 
and increasing expression of the insulin-degrading enzyme (IDE) (17).
It has been shown that oral supplementation of He extracts improved cognitive pro-
cesses in mice and improved their locomotor functions (18). A detailed analysis of bio-
chemical processes allowed to specify the suppressing effect of the He extracts on the acti-
vity of ATP-dependent calcium conductance in rat PC12 neuron-differentiation cells and 
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IC50 Units ReferenceControl cell line
Hericerin A
HL-60 3.06 ± 0.56 μmol L–1
10
HEL-299 64.61 ± 3.82 μmol L–1
Isohericerin




HL-60 5.47 ± 0.32 μmol L–1 
 10 
HEL-299 > 100 μmol L–1 
N-De phenylethyl  
isohericerin




HL-60 4.10 ± 0.21 μmol L–1
 10 
HEL-299 5.79 ± 0.60 μmol L–1
Hericenon J
HL-60 4.13 ± 0.20 μmol L–1
 10 




HL-60 4.28 ± 0.19 μmol L–1
 10 
HEL-299 8.46 ± 0.61 μmol L–1
Polysaccharide EP-1
MC Induction of apoptosis  12 
GES-1 No effect
Lectin HEA HepG2 56.1 μmol L–1  14 

























μg mL–1  13 
GES-1 – human stomach cells, HEA – Hericium erinaceus agglutinin, HEG-5 – polysaccharide-protein, HEL-299 – 
human embryonic lung cells, HepG2 – human hepatocellular carcinoma cells, HGF-1 – human fibroblasts, HL-60 
– human leukemia line, HWE – hot water eluate, IC50 – half maximal inhibitory concentration, MC – human pre-
cancerous stomach cells, MCF7 – human breast cancer cells, MWE – microwave water-ethanol eluate, MOLT-4 and 
U-937 – human leukemia cells, SGC-7901 – human stomach cancer cells
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human HOS cells. The effect of this action is to slow down the conduction of stimuli 
 dependent on P2R purinoreceptors which, in the animal model, resulted in the weakening 
of the sensation of pain stimuli caused by the heat (19). Zhang et al. (20) isolated eleven 
compounds from the fruiting bodies of He including one previously unknown – heri-
nacine K, and analysed their neurotrophic activity in vitro. The rest of the compounds were 
ergosterol peroxide, cerevisterol, 3β,5α,9α-trihydroxy-ergosta-7,22-dien-6-one, inoterpene 
A, astradoric acid C, betulin, oleanolic acid, ursolic acid, hemisceramide, 3,4-dihydro-5- 
-methoxy-2-methyl-2-(40-methyl-20-oxo-30-pentenyl)-9(7H)-oxo-2H-furo[3,4-H]benzopy-
ran. The identification of these compounds was achieved by purification of ethyl acetate 
soluble portion of an ethanol extract of dried fruiting bodies of He. PC12 cells were incu-
bated with each of the latter compounds in non-toxic concentrations of 10 and 20 μmol L–1, 
in the presence and the absence of NGF (20 ng mL–1) as a control. The data showed that 
3,4-dihydro-5-methoxy-2-methyl-2-(40-methyl-20-oxo-30-pentenyl)-9(7H)-oxo-2H- 
-furo[3,4-H]benzopyran exhibited high neurite outgrowth-promoting activity in NGF-indu-
ced PC12 cell, while ergosterol peroxide, cerevisterol and 3β,5α,9α-trihydroxy-ergosta- 
-7,22-dien-6-one had weak neuroactive activity. Fig. 1b shows the structures of isolated 
compounds.
Studies conducted among people aged 50–80 years with mild cognitive impairment 
showed that the use of orally administered powdered He fruit body at a dose of 250 mg 3× 
per day improved their cognitive function compared to the placebo group, and this effect 
persisted for 4 weeks after discontinuation of the tested supplement (21). In another study, 
a reduction in the severity of depression and anxiety was observed in women after 4 weeks 
of taking 500 mg of the powdered He fruiting body 4× per day compared to the placebo 
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Fig. 1. Chemical structures of Hericium erinaceus and Trametes versicolor components: a) identified in 
the MeOH extract of He fruiting body (10), b) identified in the ethanol extract of He fruiting body (20), 
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of women in the second experiment were randomized. However, it should be noted that 
the above-mentioned studies were carried out on small groups of 30 people in both cases. 
A summary of the results of study performed in vivo is presented in Table II.
A toxicological analysis indicated that even large doses of He extracts do not cause 
side-effects in rats. Doses of He mycelium enriched with erinacine A administered orally 
in the mentioned studies were 3–5 g kg–1 (17). A teratogenic effect of a 2625 mg kg–1 dose in 
rats was excluded. Furthermore, the mutagenic effect of He extract was not demonstrated 
on bacterial cells in the Ames test (5 mg), in vitro in the chromosomal aberration test (2.5 
mg mL–1) and in vivo in the micronucleus test in erythrocytes (5 mg kg–1). The mitogenic 
effect of He lectins on lymphocytes was also excluded (14). The few studies that described 
the use of He extracts in humans have also proven the absence of adverse effects and 
proved their good tolerance (21, 22).
The conclusions from these observations as well as the lack of reports on adverse 
 effects suggest possible benefits of using He in the treatment of chronic pain caused by 
cancer as well as complications of chemotherapy such as peripheral polyneuropathy. In 
order to confirm the described properties of He, it is necessary to conduct randomized 
studies on large cohorts of patients receiving chemotherapy and to exclude possible drug 
interactions that could adversely affect the results of evidence-based medicine (EBM) 
 therapy. Due to immunomodulatory effects, He extracts should not be used in allograft 
recipients, because of the potential risk of rejection and the development of graft-versus- 
-host disease (GvHD).
TRAMETES VERSICOLOR
Trametes versicolor (Tv, also known as Coriolus versicolor, Polyporus versicolor, yun-Zhi, 
kawaratake, Turkey tail mushroom) is a species of fungus (Polyporaceae family) used in Asian 
medicine for thousands of years, but the immunomodulatory activity of Tv was first dis-
covered in 1965 in Japan (23, 24). Tv contains two proteoglycan fractions with anticancer 
properties: K – krestin polysaccharide (PSK) and polysaccharidopeptides (PSP). In Japan, 
PSK is routinely used in oncology in patients during and after treatment. PSK was ap-
proved as an anticancer drug by the Japanese National Health Registry in 1977 (in China 
in 1987) (24). Gastric cancer was the first cancer in which PSK was used in adjuvant therapy 
(25). It is worth noting that the results of the treatment of stomach cancer in Asian  countries 
are more satisfying than in Western countries. In the meta-analysis of patients with 
colorectal cancer, it was shown that the addition of PSK to adjuvant therapy improved 
overall survival (OS) and disease-free survival (DFS) (26). Recent studies have raised the 
role of Tv in supportive therapy of breast cancer (24). In the studies on the Asian popula-
tion, an increase in 5-year survival was observed in patients with recurrent breast cancer 
after adding of PSK to standard oncological treatment (27). Moreover, the prognosis in 
patients with early breast cancer with pathological features of angioinvasion has been 
improved (28). During the three decades of Asian studies, the components of Tv were used 
as supportive therapy in cancers of the stomach, oesophagus, nasopharynx, colon, rectum 
and lung (29). With the development of immunomodulatory therapy, interest in PSK and 
PSP appeared in the last decade also in Western countries.
The immunological activity of the components of Tv extracts is the result of enhanced 
innate and acquired immune response through agonistic effects on TLR (toll-like receptor), 
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especially TLR2 and TLR4 (30–33). TLR are membrane proteins of immune cells (dendritic 
cells, macrophages), which are the first to react with antigens, triggering the release of 
pro-inflammatory cytokines and subsequent activation of T and B lymphocytes.
PSP and PSK contain the common, most biologically active component – β-glucan (34). 
TLR2 and TLR4 are immune receptors for β-glucans (32, 35). Thus, β-glucans activate a 
series of immune cells, such as monocytes, macrophages, NK cells, dendritic cells. Addi-
tionally, the results of breast cancer research suggest the effect of β-glucan obtained from 
a Tv on a potential increase in the anticancer activity of lymphocytes by reacting with the 
complement iC3b receptor (36). Monoclonal antibodies, such as trastuzumab combined 
with β-glucan have been shown to induce a greater regression of breast tumours in the 
mouse model compared to trastuzumab alone (24). It is also suggested that other monoclo-
nal antibodies known to activate complements, such as cetuximab or rituximab, would be 
more effective if combined with the β-glucan polysaccharide (37–39) (see Fig. 1c).
PSK induces the production of many cytokines, including TNF-α, IL-2, IL-6, IL-8, IL-12 
(40–42). The increase in IL-8 and IL-12 concentration after PSK induction confirms the 
 effect on lymphocytes, monocytes and macrophages circulating in the peripheral blood, 
most probably as a result of increased expression of IL-8 genes in mononuclear cells and 
IL-12 in monocytes and macrophages (24, 42). The immunomodulatory effect of PSK is 
 associated with the IL-12-dependent increase in the CD4 + Th1 cell response to tumour 
cells (43). Maintaining the advantage of Th1 responses to Th2 is perceived as beneficial in 
cancer therapy.
PSK also stimulates Tγδ lymphocytes, which are a small but significant population of 
T lymphocytes in the anti-tumour immune response. In in vitro studies, PSK increased the 
expression of CD25, CD69, CD107a and activation of Tγδ lymphocytes in tumour-infiltrat-
ing lymphocytes (TILs), the higher percentage of which is associated with a better prognosis 
for survival (44). Additionally, in response to PSK stimulation, Tγδ lymphocytes produce 
significant amounts of IFN-γ, which plays an important role in the anti-tumour response. 
The presence of activated Tγδ lymphocytes in both a direct and indirect way also affects 
the population of DC cells, which, in turn, enhance the response of T and NK cells by 
 reinforcing the production of IL-12 (44).
Furthermore, PSK is believed to stimulate NK cells and increase antibody-dependent 
cell cytotoxicity (ADCC), a leading mechanism in the control of cancer cells through TLR-2 
agonistic effects (30). Torkelson et al. (45) showed a relationship between an increase in the 
dose of Tv extract and an increase in the activity of NK cells, lymphocytes and the number 
of T cells (CD8 +) and B (CD19 +), without changes in NK cell numbers.
PSP, due to the structure similar to that of PSK, shows similar immunological activity. 
It stimulates the expression of TLR4 and TRAF6, and induces the synthesis of cytokines 
such as IL-1β, IL-6, TNF-α (33, 35). Sekhon et al. (46) observed an increase in the number of 
monocytes (CD14+/CD16-) under the influence of PSP in the absence of a direct effect on 
the proliferation of T, B and NK lymphocytes.
Both PSP and PSK will antagonize the decrease in cell counts and their immunological 
activity, contributing to the reduction of adverse effects associated with cancer treatment. 
This hypothesis was confirmed by studies conducted in animals and humans. Weneer et 
al. (47) observed a smaller decrease in leukocytes in mice after attaching PSK to docetaxel. 
Hu et al. (48) showed that adding PSP to chemotherapy based on cyclophosphamide 
9
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 reduced some of the side-effects of CTX, whereas Xu et al. (49) observed a lower rate of bone 
marrow suppression in patients receiving oxaliplatin-based chemotherapy after using PSP. 
The minimization of the frequency of side-effects of oncological therapies contributes to 
better overall survival by maintaining the rhythm of chemotherapy and improves the 
quality of life of oncological patients. Recent data suggest that Tv extract may also improve 
immune status in patients during radiotherapy, which causes specific immunodeficiency 
disorders, including lymphopenia and low NK cell activity (45). Randomized studies have 
demonstrated the benefits of using PSK not only related to the improvement in immune 
status, but also fitness status, stable body mass or reduction of symptoms associated with 
cancer, such as fatigue and malnutrition (50).
Apart from immunomodulatory activity, the antitumor activity of both components 
of the Tv was also observed. In recent experimental studies, the simultaneous use of PSK 
with docetaxel was associated with a greater regression of prostate cancer in the mouse 
model, including increased inhibition of tumour cell proliferation and intensification of 
their apoptosis in comparison with the use of taxanes alone (47).
In vitro studies have demonstrated the inhibitory effect of Tv extract on the prolifera-
tion of HeLa tumor cell lines (cervical cancer), LS174 (colorectal cancer), A549 (lung cancer) 
(51), Raji (Burkitt’s lymphoma), NB-4 and HL-60 (acute promyelocytic leukemia) (43), MCF-7, 






























































LoVo 224 54 
IC50 – half-maximal inhibitory concentration, N/A – not applicable
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MDA-MB-231, T47-D (breast cancer) (52, 53), HepG-2 (hepatocarcinoma) (52) and LoVo 
(colorectal cancer) (54) (Table III). Several studies have shown that the cytotoxic effect was 
dose-dependent and selective only for cancer cells. However, no cytotoxic activity of Tv 
extract was observed against the normal cell lines – IEC-6, Vero, WRL (23, 43) and tumour 
cell lines BT-20 (breast cancer) (53) and JCA-1 (prostate cancer) (55). Interestingly, both tu-
mour cell lines BT-20 and JCA-1 are hormone-dependent. The hypothesis of the importance 
of the hormonal status may be confirmed by studies on the inhibitory effect of Tv on the 
androgen-sensitive prostate cancer cell line LNCaP (55).
It is suggested that high doses of the extract of Tv fruiting bodies could achieve com-
parable cytotoxic efficacy as commonly used oncological drugs, with a lesser impact on 
healthy cells. Lau et al. (43) observed a comparable cytotoxic effect with more than 90 % 
growth suppression of the acute promyelocytic leukaemia cell lines (HL60, NB-4) and 
Burkitt’s lymphoma B cell line (Raji) using mitomycin C at a dose of 20 μg mL–1 and extract 
of Tv fruiting bodies at doses exceeding 3.5–4 fold the IC50 value for HL60, NB-4, Raji cells. 
In their study, cell death ELISA was used for the detection of cell death based on which 
half-maximal inhibitory concentration (IC50) for Tv extract was determined. These results 
confirm that Tv extract dose-dependently inhibits the proliferation of lymphoma and leu-
kemic cells possibly via an apoptosis-dependent pathway. However, recent studies have 
shown that mycelium extract shows a much stronger cytostatic effect than the extract  obtained 
from Tv fruiting bodies (basidiocarps) (51).
Due to the fact that PSP and PSK are obtained from the mycelium of Tv, it is expected 
that Tv proteoglycans may also be responsible for antitumor activity related to the cyto-
toxic activity. Hirahara et al. (56) showed that isolated PSK effectively inhibited the prolife-
ration of HL60 (leukaemia) cell lines, and, to a lesser extent, HT29, SW480 (colorectal 
 cancer); however, increase in the dose did not enhance the cytotoxic effect, unlike in the 
study on the extract from Tv fruiting bodies or mycelium. In turn, Hattori et al. (57) did not 
observe any PSK effect on the HL-60 cell line, not even at a dose exceeding 30 times the 
dose used in the previous study. The discrepancies in the results may be due to the differ-
ences in experimental conditions. Moreover, the results of the above studies may suggest 
the presence of another unknown substance in the Tv mycelium with a dose-dependent 
cytostatic effect.
We do not know the molecular mechanisms of Tv activity well enough to determine 
whether the visible antitumor effect is mainly associated with a direct cytotoxic activity or 
immunomodulatory properties of Tv extract. A direct comparison of the results of experi-
mental studies is difficult due to differences in the methodology. Previous studies have 
suggested that the antitumor effect may be dependent on the modulation of the major 
histocompatibility complex (MHC) and the inhibition of the nuclear factor-kappa (NF-κB) 
(58–60). Heish et al. (55) suggested that the anti-proliferative activity of Tv extract is based 
on the arrest of the cell cycle in the G1/S phase. In turn, Jiménez-Medina et al. (61) demon-
strated the suppression of the tumour cell proliferation in the G0/G1 phase. Hirahara et al. 
(56) suggested that the activation of caspase 3 by PSK may be partially responsible for 
antitumor activity against leukemic cells. These mechanisms might be synergistic and 
probably different depending on the type of cancer.
Because of the existing discrepancies, the mechanisms of cytotoxic activity of the ex-
tracts obtained from Tv, the assessment of their applicability in oncological patients in 
supportive therapy remains open and requires further research.
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The commercially available He and Tv supplements contain between 100 and 1000 mg 
of the fruiting body or mycelium powder per dose depending on the pharmaceutical manu-
facturer. Extracts are composed mainly of polysaccharides but also beta-glucans, palmitic 
acid, minerals and are dedicated to the treatment of gastrointestinal, neurological (He) and 
oncological (Tv) diseases. Daily doses of He and Tv supplements have not been officially 
established. Manufacturers’ recommendations on the daily He and Tv doses are up to 2 g. 
They are contradicted in pregnant and lactating women and children before the age of 3.
Hericium erinaceus and Trametes versicolor give rise to high hopes as sources of sub-
stances potentially useful in medicine. The substances existing in the extracts of Hericium 
erinaceus and Trametes versicolor may exhibit chemotherapy-supporting and immunomodu-
latory effects in oncological patients. Their use is more justified than that of other supple-
ments used by patients.
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